PBS Access for GLP1 Medication Moves Closer
- Mark Mellor
- 3 days ago
- 3 min read
A long-awaited shift in obesity treatment policy
For years, obesity has been recognised as a chronic, relapsing disease, yet access to effective treatments in Australia has remained limited—particularly when it comes to pharmacotherapy.
Recent signals from the Pharmaceutical Benefits Advisory Committee (PBAC) suggest that this may finally be changing.
There is now a clearer pathway emerging toward PBS subsidisation of GLP-1 receptor agonists for obesity, marking what could be one of the most significant policy shifts in metabolic health care in decades.
Why does funded access to GLP1 medication matter?
GLP-1 receptor agonists—such as semaglutide and tirzepatide—have demonstrated:
Sustained, clinically meaningful weight loss
Improvements in cardiometabolic risk factors
Reductions in cardiovascular events (as shown in major trials like SELECT)
Yet despite this, access in Australia has largely been limited to those who can afford private prescriptions.
This creates a two-tiered system, where:
Patients with diabetes may receive subsidised care
Patients with obesity—often with equal or greater health risk—do not
What is PBAC now saying?
The PBAC has indicated that PBS access for GLP1 medication
is possible, but will likely require:
1. Targeted eligibility criteria
Access may initially be limited to:
Higher-risk individuals
Those with obesity-related complications (e.g. cardiovascular disease)
2. Demonstration of cost-effectiveness
Submissions will need to clearly show:
Long-term healthcare savings
Reduction in hospitalisations and complications
3. Structured models of care
Importantly, medication alone is unlikely to be enough. PBAC is signalling a preference for:
Multidisciplinary care
Integration with lifestyle, behavioural, and medical support
Defined treatment pathways and review points
Why this approach makes sense
Obesity is not simply a matter of willpower—it is a complex neurohormonal condition influenced by:
Appetite regulation pathways
Genetics and biology
Environmental and social determinants
Effective treatment therefore requires:
The right patient, the right treatment, at the right time—within a structured care model.
This aligns strongly with international best practice and emerging frameworks such as:
Chronic disease management models
Stepped-care obesity pathways
Precision medicine approaches
The risk of getting it wrong
While PBS access is a major step forward, implementation will be critical. Potential risks include:
Overly restrictive criteria limiting access to those who would benefit
Fragmented care without appropriate clinical oversight
Over-reliance on medication without addressing underlying drivers
Without careful design, we risk replacing one inequity with another.
What needs to happen next
To truly transform obesity care in Australia, PBS funding must be accompanied by:
1. Investment in multidisciplinary care
Dietitians
Psychologists
Exercise physiologists
2. GP-led, coordinated care models
Primary care is best placed to:
Identify patients early
Provide longitudinal care
Coordinate treatment pathways
3. Equity-focused policy design
Access must prioritise:
Those at highest risk
Underserved populations
Patients currently excluded due to cost
What this means for patients
For patients, this development represents hope:
More affordable access to effective treatments
Recognition of obesity as a legitimate medical condition
A shift toward evidence-based, compassionate care
Our perspective at Perth Weight Clinic
At Perth Weight Clinic, we have long advocated for:
Equitable access to evidence-based obesity treatments
Doctor-led, multidisciplinary care
A focus on health outcomes—not just weight loss
The direction signalled by PBAC is encouraging—and aligns with the model of care we already provide.
Looking ahead
This is not the final step—but it is a crucial one. If implemented well, PBS access to GLP-1 medication could:
Reduce the burden of chronic disease
Improve quality of life for thousands of Australians
Shift the narrative from blame to biology.
Obesity care in Australia is evolving. The question now is whether we seize this opportunity to build a system that is fair, effective, and sustainable.
This article is for general information only and does not constitute medical advice. PBS availability and eligibility criteria for these medications have not yet been finalised.
Comments